During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.

This year, the EHA Congress provided us with long-term follow-up of some very interesting study, including the GAIA/CLL13 ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg ...

Venetoclax shows potential in pediatric relapsed/refractory AML/MDS, with a 41.6% overall response rate and 33% complete response rate in a single-center study. Combining venetoclax with cytotoxic ...

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of ...

Data suggest that “venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population,” the researchers wrote.

New preliminary clinical results show Annamycin plus Ara-C achieved 60% CR/CRi in subjects who were relapsed from or refractory to Venetoclax regimens; more than 4 times greater than published ...

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.